Clariant and Switzerland-based SICPA have developed Plastiward, an integrated protection system for plastic pharmaceutical packaging.
Designed to protect pharmaceutical brands and patients, Plastiward provides a two-in-one approach for medical device and pharmaceutical packaging companies.
The system has been develop based on Clariant's experience in developing polymer compounds and masterbatches, and SICPA's expertise in protecting brands and products.
The World Health Organization (WHO) has noted that more than 8% of existing medical devices are counterfeit, while Interpol estimates $75bn in counterfeit pharmaceuticals enter the market annually.
SICPA new channels and partnerships director Yann Ischi said: "Pharmaceutical companies have taken steps to reduce this risk. But the rise of e-commerce and access to new technologies has accelerated counterfeiting and other forms of illicit trade.
“That makes fighting counterfeit medical products an ever-more urgent priority for pharma companies – both in terms of patient safety and brand reputation.
"In the fight against the counterfeiting epidemic, we have to stay ahead through innovation. For plastic medical devices, SICPA combined innovation expertise with Clariant to develop Plastiward, so that our clients can focus on the needs of their patients and doctors."
Plastiward is designed to deliver SICPA's proprietary covert taggant additives to Clariant's ISO13485-certified plants, which produce materials for its Mevopur brand.
The taggants are then incorporated into various polymers used in medical devices and pharmaceutical packaging, either in a concentrated masterbatch form, or as a finished polymer compound.
After becoming part of the eventual plastic product, the taggants are readily detectable using SICPA's deployment and monitoring platform.
Once the tagged product enters the supply stream, the SICPA monitoring system can identify them at any point from factory to pharmacy.